Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers
Choa Park1,3, Yejin Lee1,3, Soyeon Je1,3, Shengzhi Chang1, Nayoung Kim1, Euna Jeong2, and Sukjoon Yoon1,2,*
1Department of Biological Sciences, Sookmyung Women’s University, Seoul 04310, Korea, 2Research Institute of Women’s Health, Sookmyung Women’s University, Seoul 04310, Korea, 3These authors contributed equally to this work.
Received May 20, 2019; Revised October 2, 2019; Accepted October 13, 2019.; Published online November 7, 2019.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

Oncogenic gain-of-function mutations are clinical biomarkers for most targeted therapies, as well as represent direct targets for drug treatment. Although loss-of-function mutations involving the tumor suppressor gene, STK11 (LKB1) are important in lung cancer progression, STK11 is not the direct target for anticancer agents. We attempted to identify cancer transcriptome signatures associated with STK11 loss-offunction mutations. Several new sensitive and specific gene expression markers (ENO3, TTC39C, LGALS3, and MAML2) were identified using two orthogonal measures, i.e., fold change and odds ratio analyses of transcriptome data from cell lines and tissue samples. Among the markers identified, the ENO3 gene over-expression was found to be the direct consequence of STK11 loss-of-function. Furthermore, the knockdown of ENO3 expression exhibited selective anticancer effect in STK11 mutant cells compared with STK11 wild type (or recovered) cells. These findings suggest that ENO3 -based targeted therapy might be promising for patients with lung cancer harboring STK11 mutations.
Keywords: Enolase 3 , lung adenocarcinoma, STK11 loss-offunction mutation
Supplementary information
Supplementary File

Current Issue

31 October 2019 Volume 42,
Number 10, pp. 687~738

This Article

Cited By Articles
  • CrossRef (0)

Social Network Service

Indexed in

  • Science Central
  • CrossMark